Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) - Total Assets
Based on the latest financial reports, Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) holds total assets worth CN¥1.69 Billion CNY (≈ $247.53 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) shareholders funds for net asset value and shareholders' equity analysis.
Zhejiang Cheng Yi Pharmaceutical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Zhejiang Cheng Yi Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Zhejiang Cheng Yi Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Cheng Yi Pharmaceutical Co Ltd's total assets of CN¥1.69 Billion consist of 22.8% current assets and 77.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.0% |
| Accounts Receivable | CN¥79.38 Million | 4.6% |
| Inventory | CN¥131.84 Million | 7.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥63.95 Million | 3.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Zhejiang Cheng Yi Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603811 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Cheng Yi Pharmaceutical Co Ltd's current assets represent 22.8% of total assets in 2024, a decrease from 51.1% in 2011.
- Cash Position: Cash and equivalents constituted 10.0% of total assets in 2024, down from 12.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 6.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 7.6% of total assets.
Zhejiang Cheng Yi Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Cheng Yi Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Zhejiang Cheng Yi Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.44 | 1.38 | 1.24 |
| Quick Ratio | 0.98 | 1.01 | 0.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥121.19 Million | CN¥130.89 Million | CN¥54.93 Million |
Zhejiang Cheng Yi Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Cheng Yi Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -8.7% |
| Total Assets | CN¥1.73 Billion |
| Market Capitalization | $568.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Cheng Yi Pharmaceutical Co Ltd's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Zhejiang Cheng Yi Pharmaceutical Co Ltd's assets decreased by 8.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zhejiang Cheng Yi Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.73 Billion ≈ $252.92 Million |
-8.68% |
| 2023-12-31 | CN¥1.89 Billion ≈ $276.97 Million |
+10.10% |
| 2022-12-31 | CN¥1.72 Billion ≈ $251.56 Million |
+29.99% |
| 2021-12-31 | CN¥1.32 Billion ≈ $193.52 Million |
+9.58% |
| 2020-12-31 | CN¥1.21 Billion ≈ $176.60 Million |
+23.12% |
| 2019-12-31 | CN¥980.25 Million ≈ $143.44 Million |
+20.13% |
| 2018-12-31 | CN¥815.99 Million ≈ $119.40 Million |
+21.25% |
| 2017-12-31 | CN¥672.98 Million ≈ $98.48 Million |
+84.75% |
| 2016-12-31 | CN¥364.27 Million ≈ $53.30 Million |
+5.24% |
| 2015-12-31 | CN¥346.13 Million ≈ $50.65 Million |
+4.98% |
| 2014-12-31 | CN¥329.72 Million ≈ $48.25 Million |
-1.23% |
| 2013-12-31 | CN¥333.83 Million ≈ $48.85 Million |
-6.78% |
| 2012-12-31 | CN¥358.12 Million ≈ $52.40 Million |
+21.12% |
| 2011-12-31 | CN¥295.68 Million ≈ $43.27 Million |
-- |
About Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs, injections, food, capsules, tablets, traditional Chinese medicines, preparations, pharmaceutical intermediates in China and internationally. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co.,… Read more